ARTICLE | Company News
Aeterna Zentaris, Solvay deal
February 6, 2006 8:00 AM UTC
SOLB returned its exclusive worldwide rights to AEZ's cetrorelix to treat benign prostatic hyperplasia (BPH). SOLB will continue to develop the GnRH/LHRH receptor antagonist to treat endometriosis. C...